Medline (NASDAQ:MDLN) Stock Price Breaks Above 200-Day Moving Average - Here's Why

Key Points

• Medline shares moved above their 200-day moving average, trading as high as $40.80 and last at $40.35, versus the average of $39.53.
• Third-quarter EPS of $0.44 beat the $0.32 consensus, with revenue of $7.86 billion; the company also raised its full-year growth outlook and announced $1 billion in share buybacks.
• Risks include a law firm’s investigation announcement related to product-quality issues and securities-fraud allegations; several analysts have also cut price targets, though the consensus rating remains “Moderate Buy.”

Medline (NASDAQ:MDLN - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $39.53 and traded as high as $40.80. Medline shares last traded at $40.35, with a volume of 25,464,548 shares changing hands.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported third-quarter EPS of $0.44, topping the $0.32 consensus estimate, on revenue of $7.86 billion. Coverage also highlighted rising net sales and an EPS beat of about 27%. Medline Q3 results
• Positive Sentiment: The company raised its full-year growth outlook, supporting expectations for continued business momentum. It also announced $1 billion in share buybacks, which could support demand for the stock. Q3 earnings and outlook Buyback coverage
• Neutral Sentiment: Some coverage said quarterly profit fell, while Medline reaffirmed its fiscal 2026 adjusted EBITDA outlook. That tempers the earnings beat but indicates no change to that profitability forecast. Profit and EBITDA outlook
• Positive Sentiment: Health Future renewed its prime-vendor agreement with Medline, extending an existing customer relationship. Prime-vendor agreement renewal
• Negative Sentiment: A law firm announced an investigation into potential securities fraud related to product-quality issues and prior stock declines. This is an investigation announcement, not a finding of wrongdoing, but it adds legal and reputational risk. Investigation announcement

Analysts Set New Price Targets

A number of research firms recently commented on MDLN. Bank of America lowered their price target on shares of Medline from $53.00 to $46.00 in a report on Thursday, August 6th. Zacks Research lowered Medline from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 20th. Truist Financial lowered their target price on shares of Medline from $56.00 to $47.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Royal Bank Of Canada lowered their price target on Medline from $53.00 to $46.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, TD Cowen dropped their price objective on shares of Medline from $53.00 to $45.00 and set a "buy" rating for the company in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.54.

Medline Price Performance

The firm has a market capitalization of $53.05 billion and a P/E ratio of 51.08. The business's 50-day simple moving average is $34.58 and its 200 day simple moving average is $39.53. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. Sell-side analysts forecast that Medline will post 1.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the firm's stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the transaction, the insider directly owned 16,453,806 shares in the company, valued at $576,705,900.30. This trade represents a 11.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 8,538,960 shares of company stock worth $302,807,442. Corporate insiders own 0.81% of the company's stock.

Institutional Trading of Medline

A number of institutional investors have recently made changes to their positions in MDLN. GAMMA Investing LLC raised its position in Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company's stock valued at $25,000 after purchasing an additional 254 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in Medline in the 1st quarter worth approximately $30,000. Reyes Financial Architecture Inc. bought a new stake in shares of Medline in the 3rd quarter worth approximately $30,000. NewEdge Advisors LLC grew its position in shares of Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company's stock worth $37,000 after buying an additional 475 shares during the last quarter. Finally, Allworth Financial LP increased its stake in shares of Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company's stock valued at $41,000 after buying an additional 487 shares during the period.

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.